



## TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

June 5, 2023

### Fireside chat scheduled for Wednesday, June 7, 2023, at 11:30 AM ET

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 2023 Jefferies Healthcare Conference, being held at the Marriott Marquis Hotel, in New York City on June 7<sup>th</sup> – 9<sup>th</sup>, 2023. The fireside chat is scheduled to take place on Wednesday, June 7, 2023, at 11:30 AM ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company's website at <http://ir.tgtherapeutics.com/events>.

### ABOUT TG THERAPEUTICS

TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received approval from the U.S. FDA for BRIUMVI® (ublituximab-xiyy), for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. For more information, visit [www.tgtherapeutics.com](http://www.tgtherapeutics.com), and follow us on Twitter [@TGTherapeutics](https://twitter.com/TGTherapeutics) and on [LinkedIn](https://www.linkedin.com/company/tgtherapeutics).

### CONTACT:

#### Investor Relations

Email: [ir@tgtxinc.com](mailto:ir@tgtxinc.com)

Telephone: 1.877.575.TGTX (8489), Option 4

#### Media Relations:

Email: [media@tgtxinc.com](mailto:media@tgtxinc.com)

Telephone: 1.877.575.TGTX (8489), Option 6